$BTSG

Nalley Lisa A sold $2.1M of BTSG

Nalley Lisa A (See Remarks) sold 35,000 shares of BrightSpring Health Services, Inc. (BTSG) at $58.75 ($2.06M total) on 2026-06-05.

Original reporting
SEC EDGAR · Nalley Lisa A
Published Jun 5, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BTSG
Neutral
medium confidence
Mentioned
$BTSG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BTSGNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider behavior but does not include new company fundamentals (earnings, guidance, contracts, trials, or litigation).

02

Market read

Traders may briefly reassess sentiment around BTSG, but the event lacks a clear fundamental catalyst.

03

What to watch

Check for other concurrent insider trades, changes in institutional ownership, and whether the sale price ($58.75) differs materially from recent trading levels.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-06-05) insider sale disclosure

Background

This is an SEC Form 4 insider transaction disclosure for BrightSpring Health Services (BTSG).

Company-level read

Ticker impact

$BTSGNeutralMedium confidence
Context

BrightSpring Health Services officer Nalley Lisa A sold 35,000 shares in an open-market transaction worth about $2.06M.

Expected impact

Likely limited/short-lived impact; watch for follow-through if selling volume persists or coincides with other disclosures.

Evidence & confidence

The filing is a routine insider transaction (open-market sale) with no stated 10b5-1 plan and no accompanying operational or financial catalyst in the article.

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Without a stated 10b5-1 plan, the sale could still be routine (tax/portfolio rebalancing) and may not signal deterioration.

Key entities

  • BrightSpring Health Services, Inc.

    Subject of the Form 4 insider sale by officer Nalley Lisa A.

  • Nalley Lisa A

    Officer who sold 35,000 shares of BTSG on 2026-06-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BTSGMedAI 8/10

BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?

BrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.

$BTSGMedAI 9/10

BrightSpring Health (BTSG) Q2 2026 Earnings Call Transcript

BrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).

$BTSGMed

5 Revealing Analyst Questions From BrightSpring Health Services’s Q2 Earnings Call

BrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.

$BTSGMedAI 8/10

BTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth

BrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.